| Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain. | None |
| Transcriptional activation of the c-myc proto-oncogene in murine keratinocytes enhances the response to epidermal growth factor. | None |
| Here we will focus on how Myc controls a number of diverse cellular processes that converge to ensure processivity and robustness of DNA synthesis, thus preventing the inherent replicative stress responses usually evoked by oncogenic lesions. | None |
| Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. | None |
| Novel interaction of the Z-DNA binding domain of human ADAR1 with the oncogenic c-Myc promoter G-quadruplex. | None |
| Amplification and overexpression of c-myc proto-oncogene correlate with the loss of glucocorticoid dependence in rodent cells transformed by human papillomavirus type 16. | None |
| [Advances of MYC oncoprotein in tumorigenesis through metabolism pathway]. | None |
| ATM deficiency allows IgH V(D)J recombination DSBs in developing B cells to generate dicentric translocations that, via BFB cycles, lead to c-myc-activating oncogenic translocations and amplifications in mature B cells. | None |
| B-cell tumors harbored oncogenic c-myc amplification generated by breakage-fusion-bridge (BFB) from dicentric chromosomes formed through fusion of IgH V(D)J recombination-associated DSBs on chromosome 12 to sequences downstream of c-myc on chromosome 15. | None |
| Mei-P26 mediates tissue-specific responses to the Brat tumor suppressor and the dMyc proto-oncogene in Drosophila. | None |
| PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. | None |
| PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. | None |
| Transactivation of proto-oncogene c-Myc by hepatitis B virus transactivator MHBs. | None |
| The c-myc oncogene is regulated independently of differentiation in myeloid cell lines. | None |
| Induction of c-fos and c-myc proto-oncogene expression by epidermal growth factor and transforming growth factor alpha is calcium-independent. | None |
| Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. | None |
| Transiently elevated levels of c-fos and c-myc oncogene messenger ribonucleic acids in cultured murine Leydig tumor cells after addition of human chorionic gonadotropin. | None |
| Search for human papillomavirus, herpes simplex virus and c-myc oncogene in human genital tumors. | None |
| Data indicate that proto-oncogene protein cMyc is required for PCAT-1-mediated cell proliferation. | None |
| Constitutive expression of c-myc oncogene confers hormone independence and enhanced growth-factor responsiveness on cells transformed by human papilloma virus type 16. | None |